Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Clinical trial NCT01532089 · COMPLETED

Trial details

NCT number: NCT01532089
Sponsor: Academic and Community Cancer Research United
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Exon 19 Deletion Mutation EGFR NP_005219.2:p.L858R Lung Non-Squamous Non-Small Cell Carcinoma Stage IV Lung Non-Small Cell Cancer AJCC v7

Start date: 2012-03-16
Primary completion: 2018-02-13
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.